{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:27:04Z","timestamp":1791311224906,"version":"4.3.1"},"reference-count":51,"publisher":"Impact Journals, LLC","issue":"37","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,11,24]]},"DOI":"10.18632\/oncotarget.4052","type":"journal-article","created":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T21:54:23Z","timestamp":1443563663000},"page":"39702-39713","source":"Crossref","is-referenced-by-count":29,"title":["mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib"],"prefix":"10.18632","volume":"6","author":[{"given":"Elyse K.","family":"Hanly","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, New York Medical College, Valhalla, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Bednarczyk","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, New York Medical College, Valhalla, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha Y.","family":"Tuli","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, New York Medical College, Valhalla, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustine L.","family":"Moscatello","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\/Head and Neck Surgery, New York Medical College, Valhalla, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Dorota","family":"Halicka","sequence":"additional","affiliation":[{"name":"Department of Pathology, New York Medical College, Valhalla, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangwei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pathology, New York Medical College, Valhalla, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Geliebter","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, New York Medical College, Valhalla, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zbigniew","family":"Darzynkiewicz","sequence":"additional","affiliation":[{"name":"Department of Pathology, New York Medical College, Valhalla, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj K.","family":"Tiwari","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, New York Medical College, Valhalla, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,5,9]]},"reference":[{"key":"1","first-page":"1291","article-title":"Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer","volume":"7","author":"Misiukiewicz","year":"2014","journal-title":"Onco Targets Ther"},{"key":"2","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomized, double-blind, phase 3 trial","volume":"384","author":"Chung","year":"2014","journal-title":"Lancet"},{"key":"3","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Taylor","year":"2015","journal-title":"N Engl J Med"},{"key":"4","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1210\/jc.2012-2104","article-title":"BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis","volume":"97","author":"Zeiger","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"5","first-page":"2333","article-title":"A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome","volume":"6","author":"Vitale","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"6","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1001\/jama.2013.3190","article-title":"Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer","volume":"309","author":"Puxeddu","year":"2013","journal-title":"JAMA"},{"key":"7","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrd3847","article-title":"Vemurafenib: the first drug approved for BRAF-mutant cancer","volume":"11","author":"Hirth","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"8","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1210\/jc.2009-0373","article-title":"Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells","volume":"95","author":"Salvatore","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"9","first-page":"958","article-title":"The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032(RG7204)","volume":"28","author":"Trink","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1756-0500-7-187","article-title":"Disruption of mutated BRAF signaling modulates thyroid cancer phenotype","volume":"7","author":"Tiwari","year":"2014","journal-title":"BMC Res Notes"},{"key":"11","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1089\/thy.2013.0057","article-title":"Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring V600E BRAF mutation","volume":"23","author":"Sherman","year":"2013","journal-title":"Thyroid"},{"key":"12","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1056\/NEJMc1215697","article-title":"BRAF V600E inhibition in anaplastic thyroid cancer","volume":"368","author":"Glaspy","year":"2013","journal-title":"N Engl J Med"},{"key":"13","first-page":"342","article-title":"Extended antitumor response of a BRAF V600E papillary thyroid carcinoma to vemurafenib","volume":"7","author":"Sharman","year":"2014","journal-title":"Case Rep Oncol"},{"key":"14","first-page":"E77","article-title":"Efficacy and tolerability of vemurafenib in patients with BRAFV600E-positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience","volume":"100","author":"Cabanillas","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"15","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1158\/2159-8290.CD-12-0531","article-title":"Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF mutant thyroid carcinomas","volume":"3","author":"Fagin","year":"2013","journal-title":"Cancer Discov"},{"key":"16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature13572","article-title":"eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies","volume":"513","author":"Kamsu-Kom","year":"2014","journal-title":"Nature"},{"key":"17","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1210\/jc.2012-3799","article-title":"Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer","volume":"98","author":"Vasko","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"18","doi-asserted-by":"crossref","first-page":"E510","DOI":"10.1210\/jc.2011-1754","article-title":"Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents","volume":"97","author":"Derwahl","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.mce.2014.05.021","article-title":"Therapeutic potential of metformin in papillary thyroid cancerand","volume":"393","author":"Park","year":"2014","journal-title":"Mol Cell Endocrinol"},{"key":"20","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/nrclinonc.2013.169","article-title":"Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates","volume":"10","author":"Rennert","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.critrevonc.2004.09.009","article-title":"Rapamycin: an anti-cancer immunosuppressant?","volume":"56","author":"Law","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"22","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/369756a0","article-title":"A mammalian protein targeted by G1-arresting rapamycin-receptor complex","volume":"369","author":"Schreiber","year":"1994","journal-title":"Nature"},{"key":"23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/bbrc.1994.2140","article-title":"A putative sirolimus(rapamycin) effector protein","volume":"203","author":"Molnarkimber","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"key":"24","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1074\/jbc.270.2.815","article-title":"Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells","volume":"270","author":"Abraham","year":"1995","journal-title":"J Biol Chem"},{"key":"25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0092-8674(94)90570-3","article-title":"RAFT1: a mammalian protein that binds to FDBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs","volume":"78","author":"Snyder","year":"1994","journal-title":"Cell"},{"key":"26","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0041-1345(03)00211-2","article-title":"Sirolimus: its discovery, biological properties, and mechanism of action","volume":"35","author":"Sehgal","year":"2003","journal-title":"Transplant Proc"},{"key":"27","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1093\/annonc\/mdt379","article-title":"A multicenter, phase 2 trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes","volume":"24","author":"Kimg","year":"2013","journal-title":"Ann Oncol"},{"key":"28","first-page":"1945","article-title":"Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays","volume":"53","author":"Darzynkiewicz","year":"1993","journal-title":"Cancer Res"},{"key":"29","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Chapman","year":"2010","journal-title":"N Engl J Med"},{"key":"30","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Lebbe","year":"2011","journal-title":"N Engl J Med"},{"key":"31","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1200\/JCO.2009.23.3452","article-title":"Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial","volume":"28","author":"Cisar","year":"2010","journal-title":"J Clin Oncol"},{"key":"32","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.1200\/JCO.2009.22.4295","article-title":"KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial","volume":"27","author":"Quirke","year":"2009","journal-title":"J Clin Oncol"},{"key":"33","first-page":"15s","article-title":"PLX4032 in metastatic colon cancer patients with mutant BRAF tumors","volume":"28","author":"Saltz","year":"2010","journal-title":"J Clin Oncol"},{"key":"34","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Bernards","year":"2012","journal-title":"Nature"},{"key":"35","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Garbe","year":"2014","journal-title":"N Engl J Med"},{"key":"36","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Mandal\u00e0","year":"2014","journal-title":"N Engl J Med"},{"key":"37","first-page":"e151","article-title":"Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAFV600E-mutant metastatic colorectal carcinoma","volume":"21","author":"Epstein","year":"2014","journal-title":"Curr Oncol"},{"key":"38","first-page":"237","article-title":"Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma","volume":"11","author":"Wargo","year":"2014","journal-title":"Cancer Biol Med"},{"key":"39","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1158\/0008-5472.CAN-07-2310","article-title":"Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells","volume":"67","author":"Sonenberg","year":"2007","journal-title":"Cancer Res"},{"key":"40","doi-asserted-by":"crossref","first-page":"10269","DOI":"10.1158\/0008-5472.CAN-06-1500","article-title":"Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells","volume":"66","author":"Pollak","year":"2006","journal-title":"Cancer Res"},{"key":"41","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1182\/blood-2010-02-269837","article-title":"The LKB1\/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation","volume":"116","author":"Dreyfus","year":"2010","journal-title":"Blood"},{"key":"42","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1042\/CS20110386","article-title":"Cellular and molecular mechanisms of metformin: an overview","volume":"122","author":"Andreelli","year":"2012","journal-title":"Clin Sci(Lond)"},{"key":"43","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bbrc.2004.06.133","article-title":"AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms","volume":"321","author":"Luo","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"44","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4161\/cc.8.1.7499","article-title":"The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells","volume":"8","author":"Menendez","year":"2009","journal-title":"Cell Cycle"},{"key":"45","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/msb.2012.30","article-title":"Metabolic rewiring drives resistance to targeted cancer therapy","volume":"8","author":"Locasale","year":"2012","journal-title":"Mol Sys Biol"},{"key":"46","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1479-5876-9-76","article-title":"Combination therapy with vemurafenib (PLX4032\/RG7204) and metformin in melanoma cell lines with distinct driver mutations","volume":"9","author":"Ribas","year":"2011","journal-title":"J Transl Med"},{"key":"47","doi-asserted-by":"crossref","first-page":"18226","DOI":"10.1073\/pnas.1317577110","article-title":"Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma","volume":"110","author":"Zheng","year":"2013","journal-title":"PNAS"},{"key":"48","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/cyto.990130802","article-title":"Features of apoptotic cells measured by flow cytometry","volume":"13","author":"Traganos","year":"1992","journal-title":"Cytometry"},{"key":"49","doi-asserted-by":"crossref","first-page":"952","DOI":"10.18632\/aging.100521","article-title":"Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling","volume":"4","author":"Darzynkiewicz","year":"2012","journal-title":"Aging"},{"key":"50","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1089\/thy.2009.0296","article-title":"Metastatic phenotype is regulated by estrogen in thyroid cells","volume":"20","author":"Tiwari","year":"2010","journal-title":"Thyroid"},{"key":"51","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3892\/or.2010.1076","article-title":"3, 3\u2032-Diindolylmethane inhibits migration and invasion of human cancer cells through combined suppression of ERK and AKT pathways","volume":"25","author":"Tiwari","year":"2011","journal-title":"Oncol Rep"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.4052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T17:36:28Z","timestamp":1589391388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.4052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,9]]},"references-count":51,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2015,11,24]]}},"alternative-id":["4052","26284586"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.4052","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,9]]}}}